Latest news with #Bruker
Yahoo
a day ago
- Business
- Yahoo
Bruker price target lowered to $50 from $61 at BofA
BofA lowered the firm's price target on Bruker (BRKR) to $50 from $61 and keeps a Buy rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on BRKR: Disclaimer & DisclosureReport an Issue NIH directs staff not to end any extra research projects for now, NY Times says Bruker's Growth Potential Driven by Innovations and Strategic Cost Management Bruker acquires biocrates life sciences, terms undisclosed Bruker launches new timsUltra AIP system Bruker unveils new proteoElute nanoLC system, PepSep Advanced nLC columns
Yahoo
2 days ago
- Business
- Yahoo
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential. Earlier in May, AbCellera Biologics announced that the US Court of Appeals for the Federal Circuit/CAFC issued a Rule 36 Order, which affirmed the validity of its US Patent No. 10,087,408 ('the '408 Patent'). The patent specifically covers microfluidic devices and their application in culturing and selectively recovering cells. Previously, Bruker Cellular Analysis Inc., which is a subsidiary of Bruker Corporation (NASDAQ:BRKR), had challenged the claims of the '408 Patent. Bruker argued for the patent's invalidity based on allegations of anticipation and obviousness in light of prior art. However, the US Patent Trial and Appeal Board/PTAB rejected all of Bruker's arguments. The CAFC's recent decision further confirms the validity of all claims within AbCellera's '408 Patent. A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform. The 408 Patent is an integral part of ongoing multi-patent infringement litigation between AbCellera and Bruker, which is currently pending in the US District Court for the Northern District of California. AbCellera intends to continue defending its intellectual property portfolio and looks forward to proving its infringement case against Bruker in the District Court. AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US. Bruker Corporation (NASDAQ:BRKR) develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Time Business News
4 days ago
- Science
- Time Business News
Utilization and Driving Factors in the Molecular Spectroscopy Market
The matter (molecules) and electromagnetic radiations has active interaction in molecular spectroscopy that are able to generate an absorption pattern or spectrum. This particular type of spectroscopy is utilized to learn more about a compound's composition or structure. The molecular spectroscopy market is growing rapidly with factors such as growing need around various industries such as food safety, environmental monitoring, pharmaceuticals and research with enhancing precision and portability of instruments with advancement in technology. Major growth aspects tailor around the tissue regeneration, embryonic development, and immune responses. Therapeutically, given aspects are more focused on wound healing, cancer treatment and regenerative medicine. Key Growth Drivers and Opportunities Molecular Spectroscopy in Pharmaceutical: Molecular spectroscopy analysis has an important role in enhancing the domain of pharmaceuticals for examining drug crystalline structures, drug identity and purity, antibiotics patent, active ingredients and excipients interactions and other aspects. Spectrophotometry is frequently utilized in bioanalysis, stability testing, impurity profiling, dissolution investigations, and pharmaceutical tests. Environmental Testing and Food Safety: Molecular spectroscopy has ability to detect chemical compositions, toxins and contaminants without any alteration in the sample which makes it highly valuable in diagnostics. It is extremely advantageous for regulatory compliance, which verifies that items meet safety regulations. Its high adoption in field-based assessments and remote sensing is due to portability and rapid response. Challenges The molecular spectroscopy falls short for determining molecule's structure completely although it is useful for molecular characteristics. Techniques including UV-Vis and IR spectroscopy may be utilized to determine functional groups and collect data on electronic transitions or vibrational modes. They cannot provide comprehensive and important details regarding atom connectivity or a molecule's three-dimensional configuration. Innovation and Expansion Thermo Fisher with Two Groundbreaking Modern Spectrometers In June 2025, Thermo Fisher introduced two cutting-edge Orbitrap mass spectrometers namely Orbitrap Astral Zoom MS for 35% faster scanning, 40% higher throughput, and 50% more multiplexing—enabling over 300 proteomes/day and Orbitrap Excedion Pro MS for EASY‑ETD fragmentation for deeper proteomics coverage used in critical in biologics characterization. Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR In April 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the 'Multi-Talent' configuration. This novel Fourier 80 'Multi-Talent' system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with dramatically enhanced versatility in benchtop FT-NMR multinuclear analysis. HORIBA Provides Contribution for Vaccine and Protein Analysis In March 2025, the HORIBA introduced Veloci which is a biopharma analyzer A-TEEM (absorbance/transmittance with fluorescence EEM), that enables label-free molecular finger prints for vaccine and protein analysis. JASCO Profits Off with its New Launch of Fluorescence Spectrophotometers In March 2021, fluorescence spectrophotometers (FP-8050 Series) which is completely new range was launched by JASCO. Given strategic launch helped the company to drive its revenue by enhancing their product portfolio. Real-time infrared spectroscopy tracks organocatalyst action Several researchers at University of Amsterdam and HFML‑FELIX used free-electron laser-based IR spectroscopy along with quantum-chemical modeling to observe the structure and binding dynamics of a thiourea organocatalyst that interacts with nitroolefin reactants. Eventually allowing the 'freezing out' reactive intermediates that makes way for rational catalyst design. Inventive Sparks, Expanding Markets The key contributors in Molecular Spectroscopy domain includes Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QUANTUM ANALYTICS, PerkinElmer Inc., Shimadzu Corporation, and others are greatly emphasizing on expanding applications into new areas including biomedicine and nanotechnology, integrating advanced data analysis capabilities, and concentrating on producing extremely delicate and portable devices. The goal of this advancement is to boost the affordability of molecular spectroscopy for on-site environmental monitoring and point-of-care diagnostics. Also, collaborations with academics in AI and machine learning have stepped up the establishment of intelligent, self-governing analytical systems. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
5 days ago
- Business
- Yahoo
New Strong Sell Stocks for June 23rd
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ares Capital ARCC is a specialty finance company, which primarily invests in U.S. middle-market companies. The Zacks Consensus Estimate for its current year earnings has been revised 7.8% downward over the last 60 days. Baidu BIDU is a Chinese-language Internet search provider. The Zacks Consensus Estimate for its current year earnings has been revised 6.5% downward over the last 60 days. Bruker BRKR designs and manufactures proprietary life science and materials research systems and associated products that serve multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. The Zacks Consensus Estimate for its current year earnings has been revised almost 5.8% downward over the last 60 days. View the entire Zacks Rank #5 List. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baidu, Inc. (BIDU) : Free Stock Analysis Report Ares Capital Corporation (ARCC) : Free Stock Analysis Report Bruker Corporation (BRKR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
BRKR Q1 Earnings Call: Tariffs and Funding Headwinds Offset by Product Innovation and Cost Actions
Scientific instrument company Bruker (NASDAQ:BRKR). reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 11% year on year to $801.4 million. The company's full-year revenue guidance of $3.52 billion at the midpoint came in 0.9% above analysts' estimates. Its non-GAAP profit of $0.47 per share was 5.9% above analysts' consensus estimates. Is now the time to buy BRKR? Find out in our full research report (it's free). Revenue: $801.4 million vs analyst estimates of $768.5 million (11% year-on-year growth, 4.3% beat) Adjusted EPS: $0.47 vs analyst estimates of $0.44 (5.9% beat) The company slightly lifted its revenue guidance for the full year to $3.52 billion at the midpoint from $3.51 billion Management lowered its full-year Adjusted EPS guidance to $2.44 at the midpoint, a 9.5% decrease Operating Margin: 4%, down from 9% in the same quarter last year Organic Revenue rose 2.9% year on year (1.6% in the same quarter last year) Market Capitalization: $6.16 billion Bruker's first quarter results reflected both the company's diversified customer base and the impact of recent acquisitions. CEO Frank Laukien highlighted that biopharma demand strengthened, and the Bruker Scientific Instruments segment achieved 5.1% organic growth, despite declining U.S. and China academic/government orders. Laukien noted that 'our teams executed very well under significant uncertainties in key markets,' and credited new product launches in spatial biology and molecular diagnostics for supporting growth. The company's BioSpin and CALID groups benefited from robust research and diagnostics activity, but the BEST segment saw a decline due to weaker MRI superconductor demand and tough comparisons from last year. Management remained cautious about the sustainability of academic/government funding, emphasizing that delayed China stimulus and new tariffs weighed on segment performance. Looking ahead, Bruker's updated guidance reflects both ongoing challenges and mitigation strategies. CEO Frank Laukien explained that U.S. policy changes and tariffs are expected to create a $100 million gross revenue headwind this year, mostly from academic/government market pressures. At the same time, Laukien outlined actions to offset these impacts, including pricing adjustments, supply chain reengineering, and cost management. CFO Gerald Herman added that mitigation efforts should cover more than half of the operating profit headwind in 2025, with full offset expected by 2026. Management remains focused on product innovation and international growth, while acknowledging that further clarity on U.S. federal research policy and global tariffs will be critical for medium-term outlooks. Management attributed first quarter growth to biopharma demand, recent acquisitions, and new product launches, but acknowledged that academic/government funding reductions and tariffs are creating significant headwinds for certain segments. Biopharma momentum: Bruker saw continued improvement in biopharma demand, with CEO Frank Laukien stating that "biopharma has been increasing from a weak base last year" and is now supported by a broader set of tools, including spatial biology and automation platforms. This trend helped offset challenges in the academic/government sector. Academic/government weakness: The company experienced a notable decline in U.S. academic and government (ACA/GOV) orders, with Laukien estimating a 20-25% revenue drop for this market in 2025. Management reported delays but not cancellations so far, and expressed uncertainty about when NIH and NSF funding would stabilize. Impact of tariffs and policy: Bruker quantified a $100 million gross revenue headwind from U.S. federal funding changes, lower China stimulus, and new import tariffs—especially a 125% Chinese tariff on some U.S. exports. CFO Gerald Herman explained that about $90 million of operating profit is at risk before mitigation actions. Recent acquisitions and product launches: The company launched new products in spatial biology, NMR (nuclear magnetic resonance), and molecular diagnostics, while integrating acquisitions like Chemspeed and ELITech. Laukien described these as "meaningful post-genomic innovations" that support growth outside of volatile funding sources. Cost and supply chain actions: To address margin pressures, Bruker is implementing targeted price increases, cost reductions, and supply network changes. Laukien said these efforts should offset more than half of the 2025 headwinds, with the remainder addressed by 2026 through further operational changes. Bruker's outlook for 2025 is shaped by anticipated weakness in academic and government markets, tariff impacts, and the pace of mitigation measures, with product innovation and international expansion as key offsetting factors. Mitigation of margin headwinds: Management expects pricing actions, cost controls, and supply chain reengineering to offset over half of the 2025 operating profit headwind, with benefits accelerating in the second half of the year and fully realized in 2026. Gerald Herman noted that supply chain adjustments and workforce flexibility, especially in Europe, will help manage fixed costs. Product innovation and diversification: Bruker is relying on new launches in spatial biology, molecular diagnostics, and automation to drive demand in biopharma and industrial markets. Laukien emphasized that recent acquisitions and expanded product offerings are helping to reduce reliance on academic/government funding and diversify revenue streams. Academic/government funding and tariffs remain risks: Management cautioned that further declines in U.S. and China academic/government funding, as well as uncertainty around future tariff policies, could continue to pressure results. The company has not assumed any major improvement in China stimulus or U.S. federal research budgets for the remainder of 2025. In the coming quarters, the StockStory team will focus on (1) evidence that cost and supply chain mitigation actions are offsetting margin and revenue headwinds as planned, (2) stabilization or recovery in U.S. and China academic/government funding trends, and (3) continued growth in biopharma and diagnostics segments supported by new product launches. Progress on integrating recent acquisitions and clarity on global tariff policies will also be key indicators. Bruker currently trades at a forward P/E ratio of 14.7×. Should you double down or take your chips? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
